Abstract. For the diagnosis of Cushing's syndrome (CS), the overnight 1 mg dexamethasone suppression test (DSt) has been widely used as a standard low-dose DSt. However, it is evident that 1 mg DSt may not be sensitive enough to detect CS when the cortisol cut-off concentration is 5 µg/dL. therefore, we developed and validated 0.5 mg DSt as a new screening method for diagnosis of aCtH-dependent CS. to compare 0.5 mg DSt with 1 mg DSt, 110 patients with aCtHdependent CS were enrolled, including 88 with Cushing's disease (CD), 8 with subclinical CD and 14 with ectopic aCtH syndrome, as well as 134 control subjects. Subjects were given either 0.5 mg or 1 mg dexamethasone orally at 23:00 on different days, with blood samples collected the following morning between 8:00 and 9:00 to determine plasma cortisol concentration. the area under the receiver operator characteristics curve observing the 0.5 mg DSt was higher than that of the 1 mg DST. The most sensitive and specific cut-off value of plasma cortisol concentration using 0.5 mg DST was found to be 3.05 µg/dL with 99.1% sensitivity and 98.4% specificity, identical to the 3 µg/dL cut-off currently used in the Japanese guideline for diagnosis of subclinical CD. In conclusion, 0.5 mg DST is a sensitive and specific screening test for diagnosis of aCtH-dependent CS. We recommend 0.5 mg DSt with a cortisol cut-off concentration of 3 µg/dL to be used as the initial step in diagnosing aCtH-dependent CS.
CUSHING'S SYNDROME (CS) can be a lethal disease as it causes excess exposure to endogenous glucocorticoids if not diagnosed and treated appropriately. It is sometimes difficult to diagnose aCtHdependent CS in the setting of Cushing's disease (CD) and ectopic aCtH syndrome (eaS) as compared with the case of aCtH-independent CS. analyzing midnight plasma cortisol levels, excretion of urinary free cortisol, and performing the low-dose dexamethasone suppression test (LDDSt) are commonly used as the initial steps in diagnosing CS [1] [2] [3] [4] [5] [6] . the endocrine Society recently reported a clinical practice guideline for diagnosis of CS [7] recommending 1 mg LDDSt to be used as one of the primary screening tests. their guidelines outlined the cut-off plasma cortisol concentration for the 1 mg LDDSt to be 1.8 µg/dL, lower than previously recommended. In general, people of Cushing's syndrome. None of participants received any medication affecting glucocorticoid metabolism, e.g. refampicin or mitotane. The clinical profiles of patients with aCtH-dependent CS and controls are summarized in table 2.
Study design
all patients and controls provided written consent. as a primary screening step for diagnosis of CS, 0.5 mg and 1 mg dexamethasone were administered orally at 23:00 hours on different days, and blood samples were collected after 30-min bed rest the following morning between 8:00 and 9:00 hours for determination of plasma cortisol concentration.
Hormone assays
Plasma aCtH was measured using immunoradiometric assay (aCtH IRMa kit, Mitsubishi kagaku Iatron, tokyo; minimum detection limit 5 pg/mL), and from east and Southeast asia are leaner than those in Western countries, thus it has been suggested that the 1 mg LDDSt may be too strong in suppressing plasma cortisol concentration in Japanese patients. In recent years, patients with subclinical CS have been diagnosed as both aCtH-independent [8] [9] [10] [11] and -dependent [12] [13] [14] . In these patients, plasma cortisol concentration is easily suppressed by DSt as their levels of excess cortisol are only mild. therefore, we attempted to develop and validate a 0.5 mg LDDSt to provide a more reliable and sensitive screening test for patients potentially suffering from aCtH-dependent CS.
Subjects and Methods

Patients and controls
We evaluated 110 patients diagnosed with aCtHdependent CS including overt CD, subclinical CD and eaS, as well as 134 controls including healthy volunteers, patients with type 2 diabetes mellitus (DM), essential hypertension and simple obesity in four independent university Hospitals (table 1) . all patients with overt CD and subclinical CD had transsphenoidal surgery (tSS) performed and their aCtH production determined by immunohistochemistry. all patients with eaS underwent surgery for original tumors and their aCtH production determined by immunohistochemistry. For the patients with type 2 DM, the LDDSt was performed after hospitalization with their plasma glucose under therapeutic control. In patients with simple obesity, pituitary and adrenal disorders were denied using clinical tests including the magnetic resonance imaging and the computed tomography. None of controls had clinical signs 
Plasma cortisol concentrations in patients with ACTH-dependent CS and controls at basal
Basal plasma cortisol concentrations in patients with aCtH-dependent CS were 31.2 ± 18.4 µg/dL, significantly higher than control subjects (14.2 ± 5.6 µg/dL, p <0.0001; table 1).
Plasma cortisol levels after 0.5 mg or 1 mg dexamethasone suppression test in controls and patients with ACTH-dependent CS.
Plasma cortisol concentrations after 0.5 and 1 mg DSts in patients with aCtH-dependent CS were greater than control subjects (27.8 ± 19.1 vs. 1.3 ± 0.7 µg/dL, p<0.0001, and 25.3 ± 19.2 vs. 1.1 ± 0.3 µg/dL, p<0.0001, respectively) ( Figures 1 and 2 ). Observing the control group, plasma cortisol concentrations after 1 mg DST were significantly lower than those after 0.5 mg DSt (1.1 ± 0.3 vs. 1.3 ± 0.7 µg/dL, p<0.05). plasma cortisol was determined by radioimmunoassay (cortisol kit, tFB, tokyo, Japan; minimum detection limit 1 µg/dL) at each hospital.
Statistical analysis
Values are expressed as mean ± SD. For continuous variables, difference between groups was analyzed using a two-tailed unpaired Student's t test. For categorical variables, differences were analyzed using a chi-square test. a probability value of p< 0.05 was considered significant. Receiver operator characteristic (ROC) plots were use to determine the threshold of each treatment. all calculations were performed using Prism v. 4.0 (Graphpad software Inc., uSa) software.
Results
Characteristics of patients and controls
the mean age of patients with aCtH-dependent CS and controls were 48.8 ± 16.1 and 45.2 ± 15.7 years old (p >0.05 by unpaired t test), respectively. the body weight of controls was greater than that of patients with aCtH-dependent CS (75.6 ± 23.2 vs. under the ROC curve of 0.5 mg DSt was greater than that of 1 mg DST. The most sensitive and specific cutoff value of plasma cortisol concentration for 0.5 mg and 1 mg DSts were 3.05 and 1.70 µg/dL, respectively (table 3) . Following the 1 mg DSt, the plasma cortisol concentration cut-off value was less than 1.70 µg/ dL, very close to the lower assay limit of most of cortisol assay kits, providing high sensitivity but low specificity. However, following the 0.5 mg DST, the plasma cortisol concentration cut-off value was 3.05 µg/dL, maintaining both high sensitivity and specificity.
Discussion
the LDDSt as well as measuring night-time plasma cortisol concentrations are used as primary screening tests in diagnosing CS. Originally, Liddle develHowever, plasma cortisol concentrations in patients with aCtH-dependent CS following 1 mg DSt did not differ from those after 0.5 mg DSt (25.3 ± 19.2 vs. 27.8 ± 19.1 µg/dL. p>0.05). Plasma cortisol concentrations after 0.5 mg and 1 mg DSts in patients with aCtH-dependent CS were highly correlated (r 2 =0.98, p<0.0001; Fig 3) .
Diagnostic utility of basal cortisol concentration and each LDDST (ROC calculation)
ROC analysis was performed on controls and patients with aCtH-dependent CS using plasma cortisol concentrations at basal conditions and following 0.5 mg or 1 mg DSts. as shown in Figure 4 , both 0.5 mg and 1 mg DSts, but not basal cortisol concentrations, were highly sensitive and specific. Basal plasma cortisol concentrations were found to be of no use. the area aCtH-dependent CS. Previously, the majority of investigators used 5 µg/ dL of plasma cortisol concentration as the cut-off value to distinguish CS from non-CS individuals. Our results using ROC analysis revealed that the cut-off value of plasma cortisol after 1 mg DSt to be 1.70 µg/dL. The sensitivity and specificity of our test was 96.2 and 98.1%, respectively. and the cut-off value was very close to that suggested in the clinical guidelines published by the endocrine Society [7] . therefore, our results support the notion that the cut-off value of plasma cortisol concentration should be lowered. However, in lowering the cut-off value the plasma cortisol immunoassays become the limiting factor as the lowest limit range of current immunoassays is about 1.0 µg/ dL. Furthermore, concentrations detected within the lower range of competitive immunoassays are less reliable than concentrations within the 'normal' range. Because of these limiting factors, it becomes apparent that using the 0.5 mg DSt with a cut-off of 3.05 µg/dL may be more useful and reliable than using a cut-off of 1.70 µg/dL following the 1 mg DSt. When using a cut-off value of less than 1.5 µg/dL, the specificity became remarkably low (88.7%). this revealed the cortisol cut-off line with the greatest power was within a very narrow range when using 1 mg DSt. In contrast, the specificity of the 0.5 mg DST was 96.1%, despite using a cut-off value of 2.75 µg/dL, which achieved 100% sensitivity. these results suggest that the 0.5 mg DSt is useful and reliable.
as we had anticipated, plasma cortisol concentrations after the 0.5 mg DST were significantly correlated with those after the 1 mg DSt. However, great prognostic value may still be of importance in patients with plasma cortisol concentrations of less than 5 µg/dL after the 1 mg DSt. Indeed, 4 CD patients and 5 subclinical CD patients were misdiagnosed when utilizing the plasma cortisol cut-off value of 5 µg/dL following the 1 mg DSt. Furthermore, 2 CD patients and 2 subclinical CD patients were missed when the cortisol cut-off was at 1.70 µg/dL. therefore, performing the 0.5 mg DSt may identify at-risk patients with greater accuracy, and is less likely to miss patients requiring treatment.
the desmopressin test is performed to differentiate pseudo-CS and healthy subjects from aCtH-dependent CS patients [25, 26] . the CRH test and inferior petrosal or cavernous sampling of plasma aCtH are performed to distinguish CD from ectopic aCtH syndrome [27] [28] [29] [30] [31] [32] . However, the specificities of these tests oped a 2 mg 2-day DSt using urinary excretion of 17-hydroxycorticosteroid [15] , while Nugent et al. built on this to develop a single dose DSt [16] . this test provided the first diagnostic test for CS. Because the radioimmunoassay for cortisol in plasma has become readily available, the DSt has now been developed into an overnight LDDSt using 1 mg dexamethasone. the 1 mg DSt is currently used as the standard screening test [5] , with a 'normal' response following 1 mg DSt to be less than 5 µg/dL plasma cortisol concentration [3, 17] . Blenthen et al. reported that the overnight 1 mg DSt suppressed plasma cortisol concentration to less than 5 µg/dL in some patients with CS, while the majority of healthy subjects had plasma cortisol concentrations of less than 2 µg/dL [18] . Findling et al. reevaluated LDDSt in patients with CS and revealed that 18% of CD were missed when the plasma cortisol cut-off value was 5 µg/dL after 1 mg DST [19] , a finding supported by Gorges et al. [20] . to increase the tests sensitivity, the plasma cortisol concentration cut-off value of 5 µg/dL after 1 mg DSt was reduced to 1.8 µg/dL [21] . this increased the sensitivity but decreased the specificity (to less than 80%) as was expected [1, 4, 19] . In 2008, the endocrine Society published a new set of clinical guidelines for the diagnosis of CS, including both aCtH-dependent and -independent types [7] . the guidelines recommend 24-h urinary free cortisol excretion, overnight 1 mg DSt, or measurement of late night salivary cortisol as initial tests. to achieve greater sensitive efficacy, the guidelines further propose that the plasma cortisol cut-off value following 1 mg DSt should be reduced to 1.8 µg/dL, as discussed above.
When the 1 mg DSt was developed, some suggested that 1 mg dexamethasone might be too strong to suppress plasma cortisol concentration in Japanese patients with CS as people in eastern and Southeastern asian countries are generally leaner than those in Western countries. In addition, subclinical CS has been found to be both adrenal [8] [9] [10] [11] and pituitary [12, 13] types. Subclinical CS frequently presents glucose intolerance [10, 22] , hyperlipidemia [10] , osteoporosis [23] , or hypertension [8] due to mild elevation of cortisol secretion, without usual signs of CS. In patients with subclinical CS, cortisol levels are usually within the normal, healthy range in the early morning, but display resistance to suppression by LDDSt [24] . therefore, we developed and evaluated the 0.5 mg DSt as a new primary screening test for diagnosis of lyze using patients with non-functioning pituitary adenoma in the future.
the Japanese clinical guidelines for the diagnosis of subclinical aCtH-independent CS recommend using a plasma cortisol concentration of 3 µg/dL as the cut-off value following the overnight 1 mg DSt. It is yet to be determined whether our current results can apply to cases of aCtH-independent CS, warranting further investigation.
In conclusion, the 0.5 mg DSt is a sensitive and specific screening test for the diagnosis of aCtHdependent CS. We recommend the 0.5 mg DSt to be used with a cortisol cut-off value of 3 µg/dL as the initial step in diagnosing aCtH-dependent CS. are not 100% accurate. therefore, to achieve an accurate and true diagnosis, the primary screening test must be not only sensitive but also specific. the current study suggests the 0.5 mg DSt to be superior to the 1 mg DSt. the present Japanese clinical guidelines for the diagnosis of CD outline the cut-off value of plasma cortisol concentration following the 0.5 mg DSt to be 3 µg/dL. using this cut-off the current study calculated the sensitivity and specificity to be identical to that of the guidelines. therefore, our results support the use of 3 µg/dL as the cortisol cut-off value for the 0.5 mg DSt. the determination of salivary cortisol obtained late at night has been recommended as one of the initial diagnostic tests due to its convenience. However, this test can detect overt CS but not subclinical CS [33] , further supporting the necessity of the 0.5 mg DSt to provide a sensitive method of diagnosing subclinical CS.
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